Chiusura precedente | 240,75 |
Aperto | 244,83 |
Denaro | 235,00 x 1200 |
Lettera | 246,15 x 900 |
Min-Max giorno | 236,25 - 245,96 |
Intervallo di 52 settimane | 208,35 - 526,00 |
Volume | |
Media Volume | 966.409 |
Capitalizzazione | 38,252B |
Beta (5 anni mensile) | 0,99 |
Rapporto PE (ttm) | 53,46 |
EPS (ttm) | 4,55 |
Prossima data utili | 03 ago 2022 - 08 ago 2022 |
Rendimento e dividendo (forward) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 358,56 |
The collaboration will explore the uptake and actionability of comprehensive genomic profiling in patients with advanced cancersSAN FRANCISCO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Syapse®, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing real-world care, today announced a partnership with Illumina, Inc. (NASDAQ:ILMN), aimed at assessing the real-world uptake and actionability of comprehensive genomic profiling in the community onc
- Business combination with Dynamics Special Purpose Corp. (Nasdaq: DYNS) is expected to provide more than $296 million in gross proceeds, over $153 million of which is fully committed in a common stock Private Investment in Public Equity (“PIPE”) financing and from non-redemption agreements - - Over $86 million in non-redemption agreements committed from existing Dynamics investors including funds managed by ARK Investment Management LLC, funds and accounts managed by Counterpoint Global (Morga
CAMBRIDGE, United Kingdom, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Dante Labs, a global leader in genomics and precision medicine, today announced the appointment of Rachel Haverfield to the company’s leadership as General Counsel to drive the growth and scale of the business and opportunity. “We are so pleased to have Rachel joining Dante’s growing leadership of top talent in the industry,” said Andrea Riposati, CEO of Dante Labs. “Rachel’s global, legal commercial, regulatory and compliance experti